The Obesity Drug Revolution: GLP-1 Agonists Are Reshaping Healthcare and the Economy

GLP-1 drugs (Ozempic, Wegovy, Mounjaro) are the biggest pharmaceutical revolution since statins. 15-20% weight loss vs 5% for previous drugs. Massive demand exceeding supply. Market projected to reach $150B by 2030. Beyond weight loss: cardiovascular benefits, reduced addiction, potential Alzheimer's application. Economic impact: reduced food consumption (snack and beverage companies worried), gym memberships declining, healthcare savings from obesity-related disease reduction. The drugs are creating both winners (Novo Nordisk, Eli Lilly) and losers across multiple industries.